Baltpharma aims to become leading producer of APIs in Russia

3 June 2019

Baltpharma, one of Russia’s leading drugmakers has announced its plans to invest about 2.1 billion roubles (~$32 million) in the building of a new plant for the production of active pharmaceutical ingredients (APIs) in the Russian St Petersburg region.

The new plant will be located on an area of 3.2 ha and will be one of the largest of its kind in Russia, notes The Pharma Letter’s local correspondent.

Most of the funds for the project will be allocated from the company’s own reserves of the company, while the remaining will be provided by the Industry Development Fund and some other Russian investment funds.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK